Vitality Biopharma recently announced it would begin trading under the stock ticker symbol VBIO.
Here's what you need to know.
1. The company is dedicated to the "development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders."
2. Adapting the new symbol is a reflection of the company's pivot to focus on the treatment of neurological and inflammatory conditions.
3. The company was focused on developing molecules through glycosylation to improve the taste of stevia. In late 2015, the company modified cannabidiol in an effort to create a novel class of pharmaceuticals known as cannbosides.
4. Cannabosides can be delivered in an oral drug format. Upon ingestion they enable therapeutic effects while reducing or eliminating the delivery of psychoactive THC to the brain. The company is currently developing a drug that could be used to treat inflammatory bowel disease.
More news related to gastroenterology and endoscopy:
1. International Association of Healthcare Professionals honors Dr. Jeffrey M. Weber: 5 things to know
2. Dr. David C. Schaefer joins Wuesthoff Medical Center: 4 things to know
3. Gastroenterologists and physician groups ask CMS to cover virtual colonoscopy: 6 points